PFE

PFE

USD

Pfizer Inc. Common Stock

$22.920+0.150 (0.659%)

실시간 가격

Healthcare
Drug Manufacturers - General
미국

가격 차트

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$22.770

고가

$23.100

저가

$22.475

거래량

3.95M

기업 기본 정보

시가총액

130.0B

산업

Drug Manufacturers - General

국가

United States

거래 통계

평균 거래량

50.85M

거래소

NYQ

통화

USD

52주 범위

저가 $20.92현재가 $22.920고가 $31.54

관련 뉴스

BusinessWire

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC)

더 보기
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Reuters

Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds

A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.

더 보기
Exclusive: US pharma tariffs would raise US drug costs by $51 bln annually, report finds
BusinessWire

Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response Guardant Health, Inc. (NASDAQ:GH), a

더 보기
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
Reuters

Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales

Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.

더 보기
Bristol Myers posts better-than-expected quarterly revenue on strong cancer drug sales
CNBC

Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump's planned pharmaceutical tariffs.

더 보기
Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
BusinessWire

Pfizer Declares Second-Quarter 2025 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock,

BusinessWire

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

More than 60 abstracts, including 15 oral and rapid oral presentations, highlight advancements across Pfizer's industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free